The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Mutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF mutations occur in roughly 5–15% of CRCs (1–3, 17)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS mutations are observed in ~ 30–45% of CRCs (1–3).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although therapies targeting EGFR have some efficacy in CRCs without KRAS mutations (1, 5–8)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“and are generally mutually exclusive with KRAS mutations (1).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationRAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Self-citationDi Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
Research works printed but not linked: 9
- 10.1158/0008-5472.CAN-06-4158 · DOI · Paper page
- 10.1200/JCO.2007.12.5906 · DOI
- 10.1200/JCO.2006.10.5437 · DOI · Paper page
- 10.1200/JCO.2008.16.7874 · DOI
- 10.1200/jco.2008.26.15_suppl.4000 · DOI
- 10.1002/ijc.2910490613 · DOI
- 10.1002/ijc.2910520107 · DOI
- 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M · DOI
- 10.1200/JCO.2001.19.11.2837 · DOI
Cited by
Sorted by citations
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436
Baldus, S. E., Schaefer, K.-L., Engers, R., Hartleb, D., Stoecklein, N. H., & Gabbert, H. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2446 · Cited by 432
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123733 · Cited by 262
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1720 · Cited by 217
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Molinari, F., Martin, V, Saletti, P., De Dosso, S., Spitale, A., Camponovo, A., Bordoni, A., Crippa, S., Mazzucchelli, L., & Frattini, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604848 · Cited by 122
Italiano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., Gugenheim, J., Becouarn, Y., Brunet, R., Fonck, M., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0864-z · Cited by 114
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
Mao, C., Wu, X.-Y., Yang, Z.-Y., Threapleton, D. E., Yuan, J.-Q., Yu, Y.-Y., & Tang, J.-L. (2015) · Scientific Reports · doi:10.1038/srep08065 · Cited by 107
Association between KRAS mutation and lung metastasis in advanced colorectal cancer
Pereira, A. A. L., Rego, J. F. M., Morris, V, Overman, M. J., Eng, C., Garrett, C. R., Boutin, A. T., Ferrarotto, R., Lee, M., Jiang, Z.-Q., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.619 · Cited by 94
Baas, J. M., Krens, L. L., Guchelaar, H.-J., Morreau, H., & Gelderblom, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0024 · Cited by 89
Watanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., Iinuma, H., Shibuya, H., & Eshima, K. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31821d37a3 · Cited by 82
Huang, F., Xu, L.-A., & Khambata-Ford, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1135 · Cited by 33
Metadata
- Authors
- Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C. S., Gambacorta, M., Lauricella, C., & Siena, S.
- Affiliations
- Falck Division of Medical Oncology, Ospedale Niguarda Ca’ Granda, Milan, Italy
- Division of Pathology, Ospedale Niguarda Ca’ Granda, Milan, Italy
- Venue
- Journal of Clinical Oncology
- Published
- 2008-09-01
- Volume
- 26
- Issue
- 25
- Pages
- 4217-4219
- ISSN
- 0732-183X
- 1527-7755
- Cited by
- 192
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
